MedTrace Logo

DOX as a Potential Treatment for Methamphetamine Dependence

NCT02785393 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-09-29

No results posted yet for this study

Summary

The purpose of the study is to asses the potential interactions between methamphetamine and doxazosin in methamphetamine-dependent volunteers who are not seeking treatment. The study will evaluate the effects of doxazosin on the cardiovascular and subjective effects of methamphetamine in a human laboratory study.

The primary objective is to determine the safety of treatment with doxazosin in methamphetamine-dependent volunteers by examining hemodynamic and subjective effects of administration of ascending doses of methamphetamine and a placebo dose during treatment with doxazosin.

The secondary objective is to determine effects of treatment with doxazosin, as compared to placebo, on subjective effects produced by administration of methamphetamine or placebo

Conditions

  • Substance-Related Disorders

Interventions

DRUG

Sugar Pill

The administration of a sugar pill

DRUG

Doxazosin

The administration of the Doxazosin medication

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Thomas F Newton, MD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785393 on ClinicalTrials.gov